OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis
Satoshi Washino, Suguru Shirotake, Hideki Takeshita, et al.
International Journal of Clinical Oncology (2023) Vol. 28, Iss. 12, pp. 1651-1658
Open Access | Times Cited: 12
Satoshi Washino, Suguru Shirotake, Hideki Takeshita, et al.
International Journal of Clinical Oncology (2023) Vol. 28, Iss. 12, pp. 1651-1658
Open Access | Times Cited: 12
Showing 12 citing articles:
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 9, pp. 949-958
Open Access | Times Cited: 14
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 9, pp. 949-958
Open Access | Times Cited: 14
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
Jeffrey A. Sparks
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 147-159
Closed Access | Times Cited: 3
Jeffrey A. Sparks
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 147-159
Closed Access | Times Cited: 3
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Yaowen Zhang, Junru Chen, Haoyang Liu, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102787-102787
Closed Access | Times Cited: 3
Yaowen Zhang, Junru Chen, Haoyang Liu, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102787-102787
Closed Access | Times Cited: 3
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab
Takayuki Nakayama, Hideki Takeshita, Makoto Kagawa, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 10, pp. 1528-1537
Closed Access | Times Cited: 2
Takayuki Nakayama, Hideki Takeshita, Makoto Kagawa, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 10, pp. 1528-1537
Closed Access | Times Cited: 2
Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer
Kaitlin R. McCarter, Senada Arabelovic, Xiaosong Wang, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 64, pp. 152335-152335
Closed Access | Times Cited: 5
Kaitlin R. McCarter, Senada Arabelovic, Xiaosong Wang, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 64, pp. 152335-152335
Closed Access | Times Cited: 5
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Yash Jani, Caroline S. Jansen, Margo B. Gerke, et al.
Immunotherapy (2024) Vol. 16, Iss. 6, pp. 405-426
Closed Access | Times Cited: 1
Yash Jani, Caroline S. Jansen, Margo B. Gerke, et al.
Immunotherapy (2024) Vol. 16, Iss. 6, pp. 405-426
Closed Access | Times Cited: 1
Immune-related adverse events can predict progression-free and overall survival in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Matteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 5, pp. 102164-102164
Closed Access | Times Cited: 1
Matteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 5, pp. 102164-102164
Closed Access | Times Cited: 1
Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy
Atsushi Yamaguchi, Yoshitaka Saito, Keisuke Okamoto, et al.
In Vivo (2024) Vol. 38, Iss. 6, pp. 2886-2896
Open Access
Atsushi Yamaguchi, Yoshitaka Saito, Keisuke Okamoto, et al.
In Vivo (2024) Vol. 38, Iss. 6, pp. 2886-2896
Open Access
Efficacy of First-Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Diego Enrico, J. Gomez, Danilo Aguirre, et al.
Clinical Lung Cancer (2024)
Closed Access
Diego Enrico, J. Gomez, Danilo Aguirre, et al.
Clinical Lung Cancer (2024)
Closed Access
